Xuanzhu Biopharm set for spin-off in Hong Kong IPO
The cash-strapped company has launched a drug to treat duodenal ulcers and is seeking approval for other products, but is up against a host of competing medicines Key Takeaways: Xuanzhu…
FAST NEWS: Sihuan Pharma stock skyrockets on latest share buyback program
The Latest: Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) on Sunday announced a new program to purchase up to HK$500 million ($64 million) worth of its shares on the open market over the next…
TransThera seeks Hong Kong IPO to sustain cancer drug research
The developer of drugs for advanced or recurrent cancers has already conducted nine financing rounds, but will not start generating commercial revenue before 2026, as all its products are still…
FAST NEWS: Four Sihuan affiliate products included in China’s national health plan
The latest: Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) announced Tuesday that four non-PVC solid-liquid double chamber bag products developed by its Beijing Ruiye affiliate have been included in the 2023 edition of…
Sihuan Pharma’s Botox Beauty Bid Suffers Covid Wrinkle
The cardiovascular and cancer drug maker’s recent shift to the medical beauty business was doing well at first, but struggled last yearKey Takeaways:Sihuan Pharmaceutical’s recent move into the medical beauty…
Recent Articles
RECENT ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
